Abstract

Most patients who develop heart failure are unable to elevate their cardiac output on demand due to impaired contractility and/or reduced ventricular filling. Despite decades of research, few effective therapies for heart failure have been developed. In part, this may reflect the difficulty of predicting how perturbations to molecular-level mechanisms that are induced by drugs will scale up to modulate system-level properties such as blood pressure. Computer modeling might help with this process and thereby accelerate the development of better therapies for heart failure. This manuscript presents a new multiscale model that uses a single contractile element to drive an idealized ventricle that pumps blood around a closed circulation. The contractile element was formed by linking an existing model of dynamically coupled myofilaments with a well-established model of myocyte electrophysiology. The resulting framework spans from molecular-level events (including opening of ion channels and transitions between different myosin states) to properties such as ejection fraction that can be measured in patients. Initial calculations showed that the model reproduces many aspects of normal cardiovascular physiology including, for example, pressure-volume loops. Subsequent sensitivity tests then quantified how each model parameter influenced a range of system level properties. The first key finding was that the End Systolic Pressure Volume Relationship, a classic index of cardiac contractility, was ∼50% more sensitive to parameter changes than any other system-level property. The second important result was that parameters that primarily affect ventricular filling, such as passive stiffness and Ca2+ reuptake via sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), also have a major impact on systolic properties including stroke work, myosin ATPase, and maximum ventricular pressure. These results reinforce the impact of diastolic function on ventricular performance and identify the End Systolic Pressure Volume Relationship as a particularly sensitive system-level property that can be targeted using multiple therapeutic strategies.

Highlights

  • Diseases caused by reduced or dysregulated contractile function are a major clinical problem

  • The results described in the following pages include sensitivity analyses that demonstrate how modulation of cell and molecular-level processes scale up to impact system-level properties

  • Heartbeats were initiated at 1 Hz by applying a pacing stimulus to a model published by ten Tusscher et al (2004) that simulates the electrophysiology of a human mid-myocardial cell

Read more

Summary

Introduction

Diseases caused by reduced or dysregulated contractile function are a major clinical problem. The clinical guidelines for heart failure (Writing Committee et al, 2013) recommend standardized therapies (primarily β-blockers and ACE inhibitors) that were developed > 30 years ago and produce a 5-year survival rate of only 50% (Benjamin et al, 2018). Given these facts, there is a pressing need to leverage the field’s everincreasing knowledge of molecular and cellular-level processes to enhance clinical care

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call